Axon Enterprise (NASDAQ:AXON) CAO Sells 1,500 Shares

Axon Enterprise, Inc (NASDAQ:AXON) CAO Jennifer Mak sold 1,500 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $573.45, for a total transaction of $860,175.00. Following the transaction, the chief accounting officer owned 12,240 shares of the company’s stock, valued at $7,019,028. This represents a 10.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON traded down $9.28 during midday trading on Wednesday, hitting $569.81. The company’s stock had a trading volume of 783,803 shares, compared to its average volume of 1,084,537. The firm has a market capitalization of $45.81 billion, a price-to-earnings ratio of 374.88, a P/E/G ratio of 12.21 and a beta of 1.46. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53. The stock has a fifty day moving average price of $537.12 and a 200 day moving average price of $621.06. Axon Enterprise, Inc has a one year low of $396.41 and a one year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The business had revenue of $796.72 million during the quarter, compared to analyst estimates of $755.29 million. During the same period in the previous year, the business earned $2.08 EPS. Axon Enterprise’s revenue was up 38.5% compared to the same quarter last year. On average, research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Morgan Stanley decreased their price target on Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Barclays decreased their target price on shares of Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Northcoast Research raised shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price target for the company in a report on Tuesday, January 6th. TD Cowen restated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. Finally, William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 3rd. Sixteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average target price of $762.93.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Earnings / growth beat: Management highlighted rapid bookings and subscription (ARR) growth on the recent earnings call, and Q4 results showed revenue and EPS beats that reinforce Axon’s shift toward higher-margin, recurring software and services. This underpins the long-term bull case. Read More.
• Positive Sentiment: Analyst support: Brokers including TD Cowen and others have raised price targets and reiterated buy/outperform views after strong bookings, supporting upside potential if execution continues. Read More.
• Neutral Sentiment: Conference visibility: Axon presented at the Morgan Stanley TMT conference; the transcript gave additional detail to investors but did not contain a major new catalyst. Increased investor outreach can help re-rating if guidance remains strong. Read More.
• Neutral Sentiment: Coverage mention: Zacks included Axon in an investment-ideas roundup — extra coverage can attract attention but typically has limited immediate impact. Read More.
• Negative Sentiment: Insider selling: An Axon insider (Isaiah Fields) sold 2,000 shares (~$1.07M at the time), trimming his stake by ~3.5%; aggregated reporting also flags other insider sales. While not necessarily a signal of company trouble, such selling can press sentiment, especially given the stock’s high valuation. Read More.
• Negative Sentiment: Valuation risk: Post-earnings commentary highlights strong growth but notes an elevated forward P/E and PEG — the stock needs continued execution to justify current multiples, making it vulnerable to profit-taking. Read More.

Hedge Funds Weigh In On Axon Enterprise

A number of institutional investors have recently made changes to their positions in the stock. Stone House Investment Management LLC purchased a new position in Axon Enterprise in the third quarter worth $29,000. New Millennium Group LLC bought a new stake in Axon Enterprise during the third quarter worth about $29,000. Darwin Wealth Management LLC bought a new stake in Axon Enterprise during the second quarter worth about $37,000. Root Financial Partners LLC purchased a new position in shares of Axon Enterprise in the 3rd quarter worth about $34,000. Finally, Creative Financial Designs Inc. ADV bought a new position in shares of Axon Enterprise during the 4th quarter valued at about $28,000. Institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.